This resource may include information that has not been approved by the US Food and Drug Administration. For full prescribing information, including. Fosphenytoin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Medscape – Epilepsy dosing for Cerebyx (fosphenytoin), frequency-based adverse contraindications, pregnancy & lactation schedules, and cost information. be expressed as phenytoin sodium equivalents (PE) when prescribing; There is.
|Published (Last):||20 November 2011|
|PDF File Size:||2.25 Mb|
|ePub File Size:||11.31 Mb|
|Price:||Free* [*Free Regsitration Required]|
Josamycin The metabolism of Fosphenytoin can be decreased when combined with Josamycin. Curcumin The metabolism of Fosphenytoin can be decreased when combined with Curcumin.
Not known hirsutism, hypertrichosis, coarsening of the facial features, enlargement of the lips, Peyronie’s disease, Dupuytren’s contracture, and drug reaction with eosinophilia and systemic symptoms DRESS see section 4.
Fosphenytoin displaces phenytoin from protein binding sites. With one exception, these reactions are commonly associated with the administration of Fospenytoin phenytoin. Folic Acid The serum concentration of Fosphenytoin can be decreased when it is combined with Folic Acid. Fentanyl The metabolism of Fentanyl inforrmation be increased when combined with Fosphenytoin.
It informahion therefore, important to eliminate other types of lymph node pathology before discontinuing therapy with Pro-Epanutin. Levothyroxine The metabolism of Levothyroxine can be increased when combined with Fosphenytoin. Rapid intravenous administration of CEREBYX increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias. Lenvatinib The metabolism of Fosphenytoin can be increased when combined with Lenvatinib.
Fosphenytoin – DrugBank
Alfaxalone The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Alfaxalone. This may or may not be associated with extravasation. Clofazimine The metabolism of Fosphenytoin can be decreased when prescribjng with Clofazimine. Levofloxacin The metabolism of Fosphenytoin can be decreased when combined with Levofloxacin. Phenytoin acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation.
HIGHLIGHTS OF PRESCRIBING INFORMATION
Bupropion The metabolism of Fosphenytoin can be decreased when combined with Bupropion. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal prwscribing channels, and therefore limit repetitive firing of action potentials. Aminophenazone The metabolism of Fosphenytoin can be decreased when combined with Aminophenazone. Phenytoin sodium equivalents PE: Candesartan cilexetil The metabolism of Fosphenytoin can be decreased when combined with Candesartan cilexetil.
Care should be taken to ensure the appropriate volume of CEREBYX is withdrawn from the vial when preparing the drug for administration. To view content sources and attributions, please refer to our editorial policy.
Eye disorders Common blurred vision, visual impairment Uncommon diplopia Ear and labyrinth disorders Common tinnitus, vertigo Uncommon hypoacusis Cardiac disorders Uncommon cardiac arrest Not known severe cardiotoxic reactions with atrial and ventricular informahion depression including bradycardia and all degrees of heart blockventricular fibrillation and cardiovascular collapse see section 4.
Adverse events seen at least twice are listed in the following, except those already included in previous tables and listings.
These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression see section 4. Hyaluronidase ovine The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Hyaluronidase.
Benmoxin The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Benmoxin. An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics.
Fosphenytoin – FDA prescribing information, side effects and uses
In patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of unbound phenytoin concentrations may be more relevant [see Dosage and Administration 2. Although resolution of symptoms may occur without treatment, skin necrosis and limb ischemia have occurred that required surgical interventions and, in rare cases, amputation.
Fosphenytoin is completely bioavailable following IM administration of Fosphenytoin Sodium Injection. Phenytoin metabolism may be reduced in patients with hepatic impairment resulting in increased plasma phenytoin concentrations see section 4. Darunavir The serum concentration of Fosphenytoin can be decreased when it is combined with Darunavir.
The background risk of fosphenyotin birth defects and miscarriage for the indicated population is unknown. Patients with an acute cerebrovascular event may be at increased risk of hypotension and require particularly close monitoring.
Phenytoin may cause increased blood glucose or serum concentrations of alkaline phosphatase and gamma glutamyl transpeptidase Fospehnytoin. Isosorbide Mononitrate The metabolism of Fosphenytoin can be decreased when combined with Isosorbide Mononitrate.
Cilansetron The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Cilansetron. Demegestone The metabolism of Fosphenytoin can be decreased when combined with Demegestone.